Skip to Content
We welcome visitors to our care settings while they’re wearing masks. View our updated visitor guidelines.

Urologic Surgery Trials

Prostate Cancer Susceptibility: The International Consortium for Prostate Cancer Genetics Study (ICPCG) 
Aims: To determine the genetic basis of prostate cancer.  Despite prostate cancer being the most commonly diagnosed cancer in men in the United States, an understanding of what makes a man genetically susceptible to prostate cancer remains unknown in most cases.  Men with a family history of prostate cancer have an increased risk of developing prostate cancer. By studying families, researchers may identify new genes or genetic alterations that specifically cause prostate cancer. Participants will donate a blood sample and complete questionnaires.
Diagnosis: Prostate cancer patients who have at least one blood relative who has been diagnosed with prostate cancer. Men and women who do not have the disease may join the study if they have two or more relatives who have been prostate cancer.
Principal Investigator: Brian Helfand, MD, PhD 
IRB Approval Number: EH13-250
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Nick Kirwen at 847.503.4281
Open to Enrollment: Yes


PROVENT: A Randomized Phase 3, Open-label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer
Aims: To learn more about a prostate cancer treatment called sipuleucel-T in early-stage prostate cancer that has not spread outside of the prostate.  Sipuleucel-T has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of late-stage prostate cancer that has spread outside of the prostate, but its use here with early-stage prostate cancer patients is considered investigational.  Two thirds of participants will be randomized to receive the sipuleucel-T and remaining third will be followed by standard care, Active Surveillance, without the investigational treatment (control group). In this way, researchers may be able to tell if the use of sipuleucel-T is helpful, or not helpful, in men with early-stage prostate cancer.
Diagnosis: Men with low or intermediate-risk prostate cancer diagnosed no longer than 12 months ago
Principal Investigator: Kristian Novakovic, MD
IRB Approval Number: EH18-381
Sponsor: Dendreon Pharmaceuticals, LLC
Contact: Study Coordinator, Julie Anderson at 847.503.3087
Open to Enrollment: Yes


REASSURE ME: Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education
Aims: To examine an 8-week health promotion and lifestyle wellness program intended to improve the quality of life in men (and their partners, if applicable) diagnosed with prostate cancer who are being followed by active surveillance.  The study will allow health care professionals to learn more about how these different health and wellness interventions work and if they should become a part of regular supportive care services for patients.
Diagnosis: Men with prostate cancer being followed by active surveillance
Principal Investigator: Kristian Novakovic, MD
IRB Approval Number: EH15-124
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Nick Kirwen at 847.503.4281
Open to Enrollment: Yes


SPORE: Tissue, Blood and Urine Banking for the Robert H. Lurie Comprehensive Cancer Center Prostate Tissue Bank
Aims: To obtain and store (bank) biospecimens and clinical data for use in future research on prostate cancer. Participants are asked to donate a blood sample (about 2 tablespoons) and allow study staff access to their medical record and any leftover prostate tissue from surgeries/procedures. Please note that, at this time, we are not collecting urine samples. The ultimate goal of the study is to use the banked specimens in research that will improve understanding of the development of prostate cancer, leading to future discoveries in prostate cancer treatment, prevention, and cure. 
Diagnosis: Men who have been diagnosed with prostate cancer 
Principal Investigator: Karen Kaul, MD
IRB Approval Number: EH01-129
Sponsors: National Institutes of Health (NIH), NorthShore University HealthSystem
Contact: Study Coordinator, Elena Genova at 224-364-7696
Open to Enrollment: Yes